XTL Biopharmaceuticals Ltd. XTLB

Company Overview

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of small-molecule therapies for oncology and immunology-related indications. The company operates within the biotechnology and pharmaceutical research industry, with an emphasis on identifying and advancing drug candidates that address unmet medical needs. XTL does not currently market approved products and does not generate recurring commercial revenue, relying instead on research and development activities and external financing.

Historically, XTL was founded in 1993 and originally focused on treatments for hepatitis B and hepatitis C. Over time, following clinical trial outcomes and strategic reassessments, the company shifted its focus toward oncology and immune-mediated diseases. Its evolution reflects a transition from antiviral research to a broader biopharmaceutical R&D model centered on targeted therapeutic mechanisms.